Evidence-based·Updated November 20, 2026·How we grade evidence

Clopidogrel

MedicationAntiplatelet (prescription)

Clopidogrel is an antiplatelet drug backed by large trials: it was modestly better than aspirin at preventing stroke, heart attack or vascular death in people with artery disease, and added to aspirin it lowered major events after acute coronary syndromes at the cost of more bleeding. Its boxed warning says it works less well in CYP2C19 poor metabolizers. Grapefruit juice is a high-severity concern in our database, and garlic and ginkgo supplements are moderate.

Taking Clopidogrel with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with acute coronary syndrome, a recent heart attack or stroke, or peripheral artery disease whose prescriber recommends clopidogrel

Common dosing range

Set by your prescriber. The Plavix label: 75 mg once daily; for acute coronary syndrome, a single 300 mg loading dose first, then 75 mg once daily with aspirin

When to expect effects

Within hours after a 300 mg loading dose; the label says starting without a loading dose delays the antiplatelet effect by several days

Watch out for

Boxed warning: less effective in people with two loss-of-function copies of the CYP2C19 gene. It raises bleeding risk, more so with NSAIDs, warfarin, other antiplatelets, SSRIs and SNRIs; stopping it early raises the risk of heart attack and stroke. The label says to avoid omeprazole and esomeprazole with it

What is it

Clopidogrel is a prescription antiplatelet medicine, a P2Y12 inhibitor, that keeps platelets from clumping into clots. It is sold as generic clopidogrel tablets and as Plavix. The Plavix label approves it to lower the rate of heart attack and stroke in people with acute coronary syndrome (unstable angina or a heart attack), given together with aspirin, and in people with a recent heart attack, a recent stroke or established peripheral artery disease.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have had an acute coronary syndrome, a recent heart attack or stroke, or have peripheral artery disease, and your prescriber recommends clopidogrel
You can take it every day as prescribed, since stopping early raises the risk of heart attack and stroke
You are willing to review every supplement, pain reliever and heartburn medicine with your doctor or pharmacist

Probably skip if…

You have active pathological bleeding, such as a bleeding ulcer or bleeding in the brain, or a serious allergy to clopidogrel (contraindicated)
Testing shows you are a CYP2C19 poor metabolizer, where the label says to consider another P2Y12 inhibitor; your prescriber decides
You take omeprazole or esomeprazole, which the label says to avoid, without your prescriber's review
You plan to stop it before surgery or dental work on your own: the timing of any pause belongs with your prescriber

Evidence at a glance

preventing stroke, heart attack and vascular death in artery disease (compared with aspirin)

Good Evidence
Effect
Small; about 9% fewer major vascular events than aspirin
Best fit
Adults with recent ischemic stroke, recent heart attack or symptomatic peripheral artery disease
Time
Measured over a mean of 1.91 years

acute coronary syndrome without ST elevation (with aspirin)

Good Evidence
Effect
Moderate; about 20% fewer major cardiovascular events, with more major bleeding
Best fit
Adults with unstable angina or non-ST-elevation heart attack also taking aspirin
Time
Treatment lasted 3 to 12 months

heart attack, mostly with ST elevation (with aspirin)

Good Evidence
Effect
Small; about 9 fewer events per 1,000 people treated for about 2 weeks
Best fit
Adults in the first day of a heart attack also taking aspirin
Time
Measured during a mean of 15 days in hospital

broad prevention in stable disease or multiple risk factors (with aspirin)

Good Evidence
Effect
No significant reduction in the main outcome
Best fit
Not applicable: the trial did not show benefit in this broad group
Time
Measured over a median of 28 months

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

preventing stroke, heart attack and vascular death in artery disease (compared with aspirin)

Disease adjunct
Good Evidence

In the blinded CAPRIE trial, 19,185 people with a recent ischemic stroke, a recent heart attack or symptomatic peripheral artery disease took clopidogrel 75 mg or aspirin 325 mg daily for 1 to 3 years (mean 1.91 years). The yearly rate of ischemic stroke, heart attack or vascular death was 5.32% on clopidogrel versus 5.83% on aspirin, a relative risk reduction of 8.7%. Intracranial bleeding (0.33% vs 0.47%) and gastrointestinal bleeding (0.52% vs 0.72%) judged severe were similar or lower.

Effect size
Small; about 9% fewer major vascular events than aspirin
Time to effect
Measured over a mean of 1.91 years
Best fit
Adults with recent ischemic stroke, recent heart attack or symptomatic peripheral artery disease
Less likely
People without established artery disease, who were not studied in CAPRIE

Bottom line: Clopidogrel alone prevented slightly more strokes and heart attacks than aspirin in people with artery disease.

acute coronary syndrome without ST elevation (with aspirin)

Disease adjunct
Good Evidence

In the CURE trial, 12,562 people seen within 24 hours of unstable angina or a non-ST-elevation heart attack took clopidogrel (300 mg, then 75 mg daily) or placebo on top of aspirin for 3 to 12 months. Cardiovascular death, heart attack or stroke occurred in 9.3% versus 11.4% (relative risk 0.80). Major bleeding rose (3.7% vs 2.7%), but life-threatening bleeding (2.2% vs 1.8%) and bleeding strokes (0.1% each) did not differ significantly.

Effect size
Moderate; about 20% fewer major cardiovascular events, with more major bleeding
Time to effect
Treatment lasted 3 to 12 months
Best fit
Adults with unstable angina or non-ST-elevation heart attack also taking aspirin
Less likely
People at high bleeding risk, in whom the extra bleeding may outweigh the benefit

Bottom line: Adding clopidogrel to aspirin after an acute coronary syndrome prevents more heart events, with more bleeding.

heart attack, mostly with ST elevation (with aspirin)

Disease adjunct
Good Evidence

In the COMMIT trial, 45,852 people admitted within 24 hours of a suspected heart attack in China took clopidogrel 75 mg or placebo daily, on top of aspirin 162 mg, until discharge or for up to 4 weeks (mean 15 days). Death, repeat heart attack or stroke fell from 10.1% to 9.2% (a 9% relative reduction), and death from any cause from 8.1% to 7.5%. Fatal, transfused or brain bleeds were not significantly more common (0.58% vs 0.55%).

Effect size
Small; about 9 fewer events per 1,000 people treated for about 2 weeks
Time to effect
Measured during a mean of 15 days in hospital
Best fit
Adults in the first day of a heart attack also taking aspirin
Less likely
People needing long-term treatment beyond the hospital stay, which COMMIT did not test

Bottom line: Clopidogrel added to aspirin early in a heart attack slightly lowered deaths and major events without excess serious bleeding.

broad prevention in stable disease or multiple risk factors (with aspirin)

No benefit found
Good Evidence

In the CHARISMA trial, 15,603 people with established cardiovascular disease or multiple risk factors took clopidogrel 75 mg or placebo on top of low-dose aspirin for a median of 28 months. Heart attack, stroke or cardiovascular death occurred in 6.8% versus 7.3%, a difference that was not significant (relative risk 0.93), while severe bleeding was 1.7% versus 1.3%. In people with risk factors only, the rate was 6.6% on clopidogrel versus 5.5% on placebo (not significant).

Effect size
No significant reduction in the main outcome
Time to effect
Measured over a median of 28 months
Best fit
Not applicable: the trial did not show benefit in this broad group
Less likely
People with risk factors but no established cardiovascular disease

Bottom line: Adding clopidogrel to aspirin for broad prevention did not significantly cut heart attacks or strokes.

How it works

Clopidogrel is a prodrug: liver enzymes, mainly CYP2C19, turn it into an active form that permanently blocks the P2Y12 receptor that platelets use to respond to ADP. The label says an affected platelet stays blocked for the rest of its life, about 7 to 10 days, even though the active form itself lasts only about 30 minutes in the blood. Because it depends on CYP2C19, anything that weakens that enzyme can weaken clopidogrel. The boxed warning covers people born with two non-working copies of the CYP2C19 gene, and the label says to avoid omeprazole and esomeprazole for the same reason. For supplements, the concern is that products with antiplatelet effects, such as concentrated garlic or ginkgo, may add to bleeding risk.

How to take it

1. Typical dose
Your prescriber sets the dose. The Plavix label: for acute coronary syndrome, a single 300 mg loading dose by mouth, then 75 mg once daily, given with aspirin; for a recent heart attack, recent stroke or established peripheral artery disease, 75 mg once daily without a loading dose.
2. Higher studied dose
The highest labeled dose is the single 300 mg loading dose for acute coronary syndrome; daily maintenance is 75 mg.
3. Timing
Once a day, at about the same time.
4. With food
The Plavix label says it can be taken with or without food; a standard breakfast lowered its platelet effect by less than 9%.
5. Split dosing
Not applicable; it is taken once daily after any loading dose.
6. How long to try
Your prescriber decides. The label says stopping early increases the risk of cardiovascular events; when it must be paused for surgery with a major bleeding risk, the label says to interrupt it 5 days before when possible and restart as soon as bleeding is controlled. Your prescriber or surgeon plans this.

What to track

Unusual bruising, nosebleeds, blood in urine, red or black stools, coughing or vomiting blood (contact your provider promptly)
Signs the label lists for thrombotic thrombocytopenic purpura, a rare blood disorder: fever, confusion or other new nervous-system symptoms, signs of kidney trouble, or unusual paleness or bleeding (seek urgent care)
Every new medicine or supplement, especially pain relievers, heartburn medicines, antidepressants and herbal products
Any planned surgery, dental work or procedure, so your prescriber can plan around it

Bottom line: Your prescriber sets the dose; take it daily as directed, talk to your prescriber before any pause, ask about heartburn medicines (the label says to avoid omeprazole and esomeprazole), and check every supplement for bleeding risk.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Bleeding, the most commonly reported adverse reaction, from bruising and nosebleeds to serious bleedingItching (more often than with aspirin in CAPRIE)Rash, diarrhea and stomach upset

Serious risks

  • Boxed warning: diminished antiplatelet effect in people with two loss-of-function alleles of the CYP2C19 gene (CYP2C19 poor metabolizers). Plavix works through an active metabolite made mainly by CYP2C19, and poor metabolizers make less of it. Tests can identify poor metabolizers, and the label says to consider another P2Y12 inhibitor for them. The label says about 2% of White and 4% of Black patients are poor metabolizers, with higher rates in Asian patients (for example 14% of Chinese).

  • Bleeding, including life-threatening and fatal bleeding. Risk rises with anticoagulants, other antiplatelet drugs and chronic NSAID use. Because affected platelets stay blocked for 7 to 10 days, the effect lasts after the last dose.

  • Stopping it raises the risk of cardiovascular events such as heart attack and stroke. The label says to restart as soon as possible after any interruption.

  • Thrombotic thrombocytopenic purpura (TTP), sometimes fatal, sometimes after less than 2 weeks of use; it needs urgent treatment. Allergic reactions can also occur, including in people who reacted to other thienopyridines.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the Plavix label says published case reports and postmarketing data have not identified a drug-associated risk of major birth defects or miscarriage, that a heart attack or stroke in pregnancy is an emergency and treatment should not be withheld over concerns about the fetus, and that clopidogrel during labor or delivery increases the risk of maternal bleeding; when possible it is stopped 5 to 7 days before labor, delivery or spinal or epidural anesthesia. Breastfeeding: the label says there are no data on clopidogrel in human milk or on milk production, no adverse effects on breastfed infants were seen in a small number of postmarketing cases, and it is found in rat milk; it says to weigh the benefits of breastfeeding against the mother's need for treatment. Discuss pregnancy and breastfeeding plans with your doctor.

Interactions

Omeprazole and esomeprazoleHigh

The Plavix label says to avoid these heartburn medicines with clopidogrel because they block CYP2C19 and significantly reduce its antiplatelet effect, even when omeprazole was taken 12 hours apart. It says dexlansoprazole, lansoprazole and pantoprazole had less effect. Ask your prescriber or pharmacist before taking any heartburn medicine, including over-the-counter ones.

NSAIDs (ibuprofen, naproxen), warfarin, other antiplatelet drugs, SSRIs and SNRIsHigh

The Plavix label says NSAIDs increase the risk of stomach and intestinal bleeding with clopidogrel, warfarin and other antiplatelet drugs add to bleeding risk, and SSRI and SNRI antidepressants may too. Aspirin is part of the prescribed regimen for some uses, but ask your pharmacist before using any over-the-counter pain reliever.

RepaglinideHigh

A clopidogrel metabolite strongly blocks the enzyme CYP2C8, and the Plavix label says clopidogrel raised exposure to the diabetes medicine repaglinide 3.9-fold to 5.1-fold. The label says to avoid the combination, or, if it cannot be avoided, to use a lower repaglinide dose with closer glucose monitoring. Your prescriber decides.

Grapefruit and grapefruit juiceHigh

Clopidogrel must be activated by enzymes including CYP2C19 and CYP3A4, which grapefruit juice inhibits. In a crossover study in 14 healthy volunteers, grapefruit juice cut the peak level of clopidogrel's active metabolite to 13% of normal, and the authors advised avoiding grapefruit juice during clopidogrel therapy; a second small study found a significantly weaker platelet effect after a loading dose but no significant difference during daily dosing. The risk is less protection against clots, not more bleeding. Avoid grapefruit, and never stop or change clopidogrel on your own.

Garlic (concentrated supplements)Moderate

Garlic compounds can make platelets less sticky, so concentrated garlic supplements may add to clopidogrel's bleeding risk. In a randomized trial in 34 healthy adults taking no antiplatelet drug, aged garlic extract at 2.4 to 7.2 g a day moderately raised the threshold for platelet clumping with some triggers and reduced platelet sticking to vessel-wall proteins, while in another study 4.2 g of raw garlic in a meal did not impair platelet function in 18 healthy volunteers. Neither study gave clopidogrel, and no study has tested garlic with clopidogrel. Tell your prescriber and pharmacist about any garlic supplement, especially before surgery or a procedure; garlic in food is not the concern.

GinkgoModerate

Ginkgo affects platelets through a different pathway from clopidogrel. In a small open-label crossover study in 10 healthy men, a single dose of ginkgo 120 mg with clopidogrel 75 mg did not increase platelet inhibition beyond clopidogrel alone 6 hours later. In a hospital records study in Vietnam of patients prescribed ginkgo extract, clopidogrel was among the co-prescribed drugs significantly associated with bleeding and abnormal clotting tests, an association that does not prove cause. Ask your prescriber or pharmacist before combining them, and mention ginkgo before any surgery or procedure.

Documented interactions

Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.

Warnings (3)

+ grapefruit

high

Clopidogrel is a prodrug: liver and gut enzymes, including CYP2C19 and CYP3A4, turn it into the active form that stops platelets from clumping. In a crossover study in 14 healthy volunteers, grapefruit juice cut the peak level of clopidogrel's active metabolite to 13% of normal, and the authors concluded grapefruit juice is best avoided during clopidogrel therapy. A second small study in healthy volunteers found a significantly weaker platelet effect after a loading dose taken with grapefruit juice, but no significant difference during daily dosing, and its authors called the evidence insufficient for a firm conclusion.

+ garlic

moderate

Clopidogrel blocks the platelet P2Y12 ADP receptor to prevent clots. Concentrated garlic supplements may also make platelets less sticky: in a trial in 34 healthy adults, aged garlic extract at 2.4 to 7.2 g a day moderately inhibited platelet clumping and adhesion, while 4.2 g of raw garlic in a meal did not impair platelet function in 18 volunteers. No study has tested garlic with clopidogrel, so any added bleeding risk is predicted from mechanism. Culinary garlic in food amounts is not a meaningful concern.

+ ginkgo

moderate

Clopidogrel blocks the platelet P2Y12 ADP receptor, while ginkgo acts on platelets through a separate pathway. In a small open-label study in 10 healthy men, a single dose of ginkgo with clopidogrel did not increase platelet inhibition beyond clopidogrel alone 6 hours later. In a hospital records study of patients prescribed ginkgo extract, clopidogrel was among the co-prescribed drugs associated with bleeding and abnormal clotting tests, an association that does not prove cause, and case reports describe bleeding with ginkgo alone. The realistic concern is a modest, additive bleeding risk, most relevant in older patients and those also taking aspirin.

See all 3 Clopidogrel interactions →

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Plavix or generic clopidogrel tablets dispensed by a licensed pharmacy on your own prescription
The tablet strength on the label (75 mg or the 300 mg loading-dose tablet)
A Medication Guide with each fill, which explains the bleeding, stopping-early and CYP2C19 warnings
Your pharmacy's interaction check against heartburn medicines, pain relievers and antidepressants

Be skeptical of…

"Natural blood thinner" supplements (garlic, ginkgo, fish oil, turmeric) presented as a replacement for clopidogrel
Supplements marketed as safe with antiplatelet drugs without evidence
Advice to stop or pause clopidogrel on your own before dental work or surgery
Online sellers offering clopidogrel without a prescription

Frequently asked questions

Can I take garlic supplements with clopidogrel?⌄

This page rates concentrated garlic supplements a moderate-severity interaction. Aged garlic extract reduced platelet stickiness in healthy adults, so it may add to bleeding risk, although no study has tested it with clopidogrel. Garlic in food did not affect platelets in a small study. Tell your prescriber and pharmacist about any garlic supplement, especially before a procedure.

Is ginkgo safe with clopidogrel?⌄

This page rates ginkgo a moderate-severity interaction. A small single-dose study in healthy men found no extra platelet effect, but hospital records linked ginkgo plus clopidogrel to bleeding and abnormal clotting tests. Ask your prescriber or pharmacist before combining them.

Can I take omeprazole or other heartburn medicines with clopidogrel?⌄

The Plavix label says to avoid omeprazole and esomeprazole because they significantly reduce clopidogrel's effect. It says lansoprazole, dexlansoprazole and pantoprazole had less effect. Ask your prescriber or pharmacist which heartburn treatment is right for you.

What does the CYP2C19 warning mean?⌄

Clopidogrel has to be activated by the liver enzyme CYP2C19. People born with two non-working copies of the gene make less of the active form, so the drug protects them less. A test can identify them, and the label says to consider another antiplatelet drug. Ask your prescriber whether testing applies to you.

Should I stop clopidogrel before surgery or dental work?⌄

Only if your prescriber or surgeon tells you to. The label says stopping raises the risk of heart attack and stroke, and when a pause is needed for surgery with a major bleeding risk it describes stopping 5 days before and restarting as soon as bleeding is controlled. They will plan this with you.

References by claim

preventing stroke, heart attack and vascular death in artery disease (compared with aspirin)

CAPRIE Steering Committee et al., 1996 · PubMed (1996) link

acute coronary syndrome without ST elevation (with aspirin)

Yusuf et al., 2001 · PubMed (2001) link

heart attack, mostly with ST elevation (with aspirin)

Chen et al., 2005 · PubMed (2005) link

broad prevention in stable disease or multiple risk factors (with aspirin)

Bhatt et al., 2006 · PubMed (2006) link

Safety

Plavix (clopidogrel) prescribing information · DailyMed (FDA label) link

Interaction: Garlic (concentrated supplements)

Steiner et al., 2001 · PubMed (2001) link

Scharbert et al., 2007 · PubMed (2007) link

Interaction: Ginkgo

Aruna et al., 2007 · PMC (2007) link

Mai et al., 2025 · PMC (2025) link

Interaction: Grapefruit and grapefruit juice

Holmberg et al., 2014 · PubMed (2014) link

Campbell et al., 2014 · PMC (2014) link

Track Clopidogrel with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 20, 2026·Evidence current as of Nov 20, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.